Logo

MorphoSys and Incyte's Minjuvi (tafasitamab) + Lenalidomide Receive EC's Approval for the Treatment of R/R DLBCL

Share this

MorphoSys and Incyte's Minjuvi (tafasitamab) + Lenalidomide Receive EC's Approval for the Treatment of R/R DLBCL

Shots:

  • The conditional approval is based on the P-II L-MIND study evaluating the safety and efficacy of tafasitamab + lenalidomide in patients with r/r DLBCL who are not eligible for ASCT
  • Results: ORR (56.8%); CR rate (39.5%); PR rate (17.3%) as assessed by an IRC; m-DoR (43.9mos.) after a minimum follow up of 35mos.
  • Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb & is co-marketed by both companies under the brand name Monjuvi in the US & Minjuvi in the EU. Additionally- both companies share global development rights for the therapy

| Ref: Incyte | Image: Morphosys US

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions